

METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM ATRIAL FIBRILLATION



Business area

Diagnostics

Market sector

*Cardiology Diagnostics
kits*

Medical Indication

*Patients undergoing
catheter ablation of AF*

Research goal

Atrial fibrillation (AF) is one of the most prevalent arrhythmia in the world (2% in population younger than 65 and 10% in older than 65 years old). The CABANA trial has determined that Catheter ablation, for controlling the rhythm, was more effective than drug therapy. However, its efficiency is reduced in 40% of AF patients.

Problem to solve

A new noninvasive and personalized strategy for predicting the response of patients suffering from AF to catheter ablation treatment.

Innovation

There is any biomarker recommended by European Guidelines for ruling out patients with a low probability of catheter ablation successful. We identify a new strategy that consists on the combined determination of two biomarkers (FABP4, adiposity biomarker, and Galectin-3, fibrosis biomarker) and AF type for identifying patients with higher probability of recurrence after catheter ablation.

Market opportunity

The global AF treatment market grew at a CAGR of around 14% during 2014-2019. The rising prevalence of cardiovascular diseases (CVDs) is one of the key factors driving the growth of the market. The efficiency of medical strategies for reestablish sinus rhythm is not 100%. Looking forward, the publisher expects the market to continue its strong growth during the next five years based on diagnosis, prognosis and monitoring therapies-biomarkers.

Research team


Moisés Rodríguez Mañero (young electrophysiologist in Clinical Hospital of Santiago de Compostela with more than 130 publications in some of the best electrophysiology's journals, i.e. Heart Rhythm, Circ Arrhythm Electrophysiol, Europace..., coordinator of research at Cardiology department of Clinical Hospital of Santiago de Compostela). Principal investigator of public and private proposals.

Sonia Eiras Penas (Dr. Biology (2003), obtained a competitive research fellow, Isidro Parga Pondal (2006) for establish a new research on epicardial fat and cardiovascular biomarkers. She has published more than 55 articles in Cardiovascular Research, Obesity Reviews, Journal of Molecular and Cellular Cardiology....coordinator of translational cardiology group. She is Principal Investigator in public and private proposals.

Intellectual property

Spanish patent **EP21382416**

Development stage:



Available for: *Licensing, co-development*